Incyte Corp. | Income Statement

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
355
511
754
1,106
1,536
1,882
Cost of Goods Sold (COGS) incl. D&A
30
44
49
104
110
128
Gross Income
325
467
704
1,002
1,426
1,754
SG&A Expense
341
472
654
838
1,662
1,599
EBIT
16
5
51
164
236
155
Unusual Expense
29
-
5
22
87
70
Non Operating Income/Expense
-
-
2
-
-
32
Interest Expense
39
47
46
39
7
2
Pretax Income
83
49
8
107
312
115
Income Tax
-
-
1
3
1
6
Consolidated Net Income
83
48
7
104
313
109
Net Income
83
48
7
104
313
109
Net Income After Extraordinaries
83
48
7
104
313
109
Net Income Available to Common
83
48
7
104
313
109
EPS (Basic)
0.56
0.29
0.03
0.54
1.53
0.51
Basic Shares Outstanding
148
168
180
188
205
212
EPS (Diluted)
0.56
0.29
0.03
0.54
1.53
0.51
Diluted Shares Outstanding
148
168
187
194
205
216
EBITDA
13
37
96
222
184
210
Non-Operating Interest Income
1
3
5
5
18
-

About Incyte

View Profile
Address
1801 Augustine Cut-Off
Wilmington Delaware 19803
United States
Employees -
Website http://www.incyte.com
Updated 07/08/2019
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late stage development, and commercialized products such as JAKAFI (ruxolitinib), and ICLUSIG (ponatinib). The company was founded by Roy A.